Uric Acid Study in Healthy Male Volunteers

AstraZeneca24 enrolled

Overview

This study is being conducted to examine the effect of AZD6140 on the levels of certain chemicals in subjects' blood and urine.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

DOUBLE

Enrollment

Conditions

Gout Coronary Artery Disease

Interventions

AZD6140DRUG

Oral tablets taken bid for 5 days

Placebo to match AZD6140DRUG

Oral tablets taken bid for 5 days

Eligibility

Sex: MALEMin age: 18 YearsMax age: 45 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Normal physical examination, vital signs, electrocardiogram (ECG) and laboratory values (unless the investigator considers an abnormality not to be clinically significant) * Normal laboratory tests at screening * Non-smoker (no cigarette/tobacco use for at least 6 months) Exclusion Criteria: * Personal or family history of gout, gouty arthritis, or renal stones

Outcomes

Primary Outcomes

The effect of AZD6140 on the levels of certain chemicals in subjects' blood and urine.

Time frame: Levels or certain chemicals in subjects' blood and urine will be measured at scheduled times during the first 7 days of the study.

Secondary Outcomes

The blood levels of AZD6140 in various subjects on the same diet.

Time frame: following dosing during the first 5 days of the study

The effect of taking AZD6140 on the levels of certain hormones in urine

Time frame: during the first 5 days of the study

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.